Table 2.
Association between Clinicopathological Factors with c-MYC Expression in T- and NK- NHL Patients (n=32).
| Variables | C-MYC | p valuea | |
|---|---|---|---|
| Negative n (%) | Positive n (%) | ||
| Age | |||
| Less than 60 | 7 (29.2) | 17 (70.8) | 0.15 |
| More than 60 | 0 (0.0) | 8 (100.0) | |
| Race | |||
| Malay | 6 (20.7) | 23 (79.3) | 0.541 |
| Chinese | 1 (50.0) | 1 (50.0) | |
| Indian | 0 (0.0) | 1 (100.0) | |
| Gender | |||
| Male | 4 (19.0) | 17 (81.0) | 0.667 |
| Female | 3 (27.3) | 8 (72.7) | |
| Site | |||
| Nodal | 2 (20.0) | 8 (80.0) | >0.950 |
| Extra nodal | 5 (22.7) | 17 (77.3) | |
| Extra nodal | |||
| Less than 1 | 5 (20.0) | 20 (80.0) | 0.653 |
| More than 1 | 2 (28.6) | 5 (71.4) | |
| Ann-Arbor staging | |||
| I-II | 1 (6.3) | 15 (93.8) | 0.083 |
| III-IV | 6 (37.5) | 10 (62.5) | |
| LDH value | |||
| Normal | 4 (28.6) | 10 (71.4) | 0.669 |
| Elevated | 3 (16.7) | 15 (83.3) | |
| ECOG | |||
| Less than 2 | 4 (26.7) | 11 (73.3) | 0.678 |
| More than 2 | 3 (17.6) | 14 (82.4) | |
| B symptoms | |||
| Yes | 2 (16.7) | 10 (83.3) | 0.683 |
| No | 5 (25.0) | 15 (75.0) | |
| IPI score | |||
| 0 to 2 | 4 (25.0) | 14 (77.8) | >0.950 |
| 3 to 4 | 3 (18.8) | 11 (78.6) | |
| T/NK-cell NHL subtypes | |||
| ALCL, ALK not done | 1 (100.0) | 0 (0.0) | 0.43 |
| ALCL, ALK-negative | 0 (0.0) | 1 (100) | |
| ALCL, ALK-positive | 2 (33.3) | 4 (66.7) | |
| AITL | 0 (0.0) | 1 (100.0) | |
| ENK/T-cell, nasal type | 0 (0.0) | 3 (100.0) | |
| PTCL, NOS | 2 (33.3) | 4 (66.7) | |
| TLL | 1 (16.7) | 5 (83.3) | |
| T-cell lymphoma | 1 (12.5) | 7 (87.5) | |
| Mortality | |||
| Alive | 1 (33.3) | 2 (66.7) | 0.85 |
| Dead | 3 (27.3) | 8 (72.7) | |
| Unknown | 3 (16.7) | 15 (83.3) | |
P values were calculated by Fisher’s exact test (two-sided)a and were considered to be statistically significant if p < 0.05